An examination of β-cell function measures and their potential use for estimating β-cell mass

Diabetes, Obesity and Metabolism

Volumn 10, Issue SUPPL. 4, 2008, Pages 63-76

  Kahn, Steven E ^a,c   Carr, D B ^b   Faulenbach, M V ^a   Utzschneider, K M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Arginine; C peptide; Diabetes mellitus; Glucose potentiation; Impaired glucose tolerance; Insulin; Intravenous glucose; Obesity; OGTT

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; NICOTINIC ACID; STREPTOZOCIN; VILDAGLIPTIN;

ANIMAL MODEL; CELL DAMAGE; CELL VOLUME; CONFERENCE PAPER; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MATURITY ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET BETA CELL MASS; PANCREAS ISLET CELL FUNCTION; PANCREAS RESECTION;

EID: 53549130683     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00945.x     Document Type: Conference Paper

References (81)

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
2. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39: 1157-1175.
3. Opie E. The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islets of Langerhans. J Exp Med 1901; 5: 527-540.
4. Maclean N, Ogilvie RF. Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 1955; 4: 367-376.
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
6. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-229.
7. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981; 70: 579-588.
8. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 1984; 7: 491-502.
9. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985; 4: 110-125.
10. Bagdade JD, Bierman EL, Porte D Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967; 46: 1549-1557.
11. Kahn SE, Prigeon RL, McCulloch DK et al. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-1672.
12. Van Assche FA, Aerts L, De Prins F. A morphological study of the endocrine pancreas in human pregnancy. Br J Obstet Gynaecol 1978; 85: 818-820.
13. Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990; 162: 1008-1014.
14. Camastra S, Manco M, Mari A et al. β-cell function in morbidly obese subjects during free living: Long-term effects of weight loss. Diabetes 2005; 54: 2382-2389.
15. Utzschneider KM, Carr DB, Barsness SM, Kahn SE, Schwartz RS. Diet-induced weight loss is associated with an improvement in β-cell function in older men. J Clin Endocrinol Metab 2004; 89: 2704-2710.
16. Kahn SE, Beard JC, Schwartz MW et al. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38: 562-568.
17. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
18. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves β-cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530-537.
19. Kahn SE, Larson VG, Schwartz RS et al. Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging. J Clin Endocrinol Metab 1992; 74: 1336-1342.
20. Cnop M, Vidal J, Hull RL et al. Progressive loss of β-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007; 30: 677-682.
21. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 942-947.
22. Ward WK, Johnston CLW, Beard JC, Benedetti TJ, Halter JB, Porte D Jr. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 1985; 34: 861-869.
23. Metz SA, Halter JB, Robertson RP. Paradoxical inhibition of insulin secretion by glucose in human diabetes mellitus. J Clin Endocrinol Metab 1979; 48: 827-835.
24. Utzschneider KM, Prigeon RL, Carr DB et al. Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care 2006; 29: 356-362.
25. Godsland IF, Jeffs JA, Johnston DG. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 2004; 47: 1157-1166.
26. Imamura T, Koffler M, Helderman JH et al. Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia. Diabetes 1988; 37: 600-609.
27. Menge BA, Tannapfel A, Belyaev O et al. Partial pancreatectomy in adult humans does not provoke β-cell regeneration. Diabetes 2008; 57: 142-149.
28. Ward WK, Wallum BJ, Beard JC, Taborsky GJ Jr, Porte D Jr. Reduction of glycemic potentiation: A sensitive indicator of β-cell loss in partially pancreatectomized dogs. Diabetes 1988; 37: 723-729.
29. McCulloch DK, Raghu PK, Johnston C et al. Defects in β-cell function and insulin sensitivity in normoglycemic streptozocin-treated baboons: A model of preclinical insulin-dependent diabetes. J Clin Endocrinol Metab 1988; 67: 785-792.
30. McCulloch DK, Kahn SE, Schwartz MW, Koerker DJ, Palmer JP. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. J Clin Invest 1991; 87: 1395-1401.
31. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer JP. Correlations of in vivo β-cell function tests with β-cell mass and pancreatic insulin content in streptozocin-administered baboons. Diabetes 1991; 40: 673-679.
32. Marchetti P, Bugliani M, Lupi R et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 2007; 50: 2486-2494.
33. Deng S, Vatamaniuk M, Huang X et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004; 53: 624-632.
34. Cerasi E. Potentiation of insulin release by glucose in man. I. Quantitative analysis of the enhancement of glucose-induced insulin secretion by pretreatment with glucose in normal subjects. Acta Endocrinol 1975; 79: 483-501.
35. Cerasi E. Potentiation of insulin release by glucose in man. II. Role of the insulin response, and enhancement of stimuli other than glucose. Acta Endocrinol 1975; 79: 502-510.
36. Halter JB, Graf RJ, Porte D Jr. Potentiation of insulin secretory responses by plasma glucose levels in man: Evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation. J Clin Endocrinol Metab 1979; 48: 946-954.
37. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74: 1318-1328.
38. Røder ME, Porte D Jr, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B-cell secretory capacity in patients with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 604-608.
39. Kahn SE, Klaff LJ, Schwartz MW et al. Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. J Clin Endocrinol Metab 1990; 71: 994-1002.
40. Seaquist ER, Robertson RP. Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors. J Clin Invest 1992; 89: 1761-1766.
41. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995; 96: 520-527.
42. Byrne MM, Sturis J, Clement K et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994; 93: 1120-1130.
43. Byrne MM, Sturis J, Fajans SS et al. Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20. Diabetes 1995; 44: 699-704.
44. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345: 971-980.
45. Shih DQ, Screenan S, Munoz KN et al. Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. Diabetes 2001; 50: 2472-2480.
46. Terauchi Y, Takamoto I, Kubota N et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117: 246-257.
47. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-29.
48. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. American Diabetes Association GENNID Study Group. β-cell function is the major determinant of oral glucose tolerance in four ethnic groups in the United States. Diabetes 2002; 51: 2170-2178.
49. Utzschneider KM, Prigeon RL, Tong J et al. Within-subject variability of measures of beta cell function derived from a 2 h OGTT: Implications for research studies. Diabetologia 2007; 50: 2516-2525.
50. The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: Effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414.
51. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
52. Chen M, Halter JB, Porte D Jr. The role of dietary carbohydrate in the decreased glucose tolerance of the elderly. J Am Geriatr Soc 1987; 35: 417-424.
53. Utzschneider KM, Tong J, Montgomery B et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and Insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008; 31: 108-113.
54. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001; 50: 150-158.
55. Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: Role of potentiation. Diabetes 2002; 51(Suppl. 1): S221-S226.
56. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: A new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
57. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
58. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186-193.
59. Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 2006; 38: 838-844.
60. Lang DA, Matthews DR, Burnett M, Ward GM, Turner RC. Pulsatile, synchronous basal insulin and glucagon secretion in man. Diabetes 1982; 31: 22-26.
61. Lang DA, Matthews DR, Burnett M, Turner RC. Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes 1981; 30: 435-439.
62. O'Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 1988; 318: 1225-1230.
63. Porksen N. Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes. Diabetes Nutr Metab 2002; 15(Suppl.): 9-14.
64. Bergstrom RW, Fujimoto WY, Teller DC, De Haen C. Oscillatory insulin secretion in perifused isolated rat islets. Am J Physiol 1989; 257: E479-E485.
65. Marchetti P, Scharp DW, McLear M et al. Pulsatile insulin secretion from isolated human pancreatic islets. Diabetes 1994; 43: 827-830.
66. Larsen MO, Gotfredsen CF, Wilken M, Carr RD, Porksen N, Rolin B. Loss of beta-cell mass leads to a reduction of pulse mass with normal periodicity, regularity and entrainment of pulsatile insulin secretion in Gottingen minipigs. Diabetologia 2003; 46: 195-202.
67. Saad MF, Kahn SE, Nelson RG et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1990; 70: 1247-1253.
68. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental insulin resistance. Diabetologia 1987; 30: 698-702.
69. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997; 46: 1725-1732.
70. Røder ME, Kahn SE. Suppression of beta-cell secretion by somatostatin does not fully reverse the disproportionate proinsulinemia of type 2 diabetes. Diabetes 2004; 53(Suppl. 3): S22-S25.
71. Poitout V, Robertson RP. Glucolipotoxicity: Fuel excess and β-cell dysfunction. Endocr Rev 2008; 29: 351-366.
72. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet β-cell failure: A link between type 1 and type 2 diabetes. J Mol Med 2003; 81: 455-470.
73. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3629-3643.
74. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
75. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.
76. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003; 26: 791-798.
77. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
78. Mari A, Scherbaum WA, Nilsson PM et al. Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008; 93: 103-109.
79. Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med 2006; 12: 144-148.
80. Simpson NR, Souza F, Witkowski P et al. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol 2006; 33: 855-864.
81. Virostko J, Chen Z, Fowler M, Poffenberger G, Powers AC, Jansen ED. Factors influencing quantification of in vivo bioluminescence imaging: application to assessment of pancreatic islet transplants. Mol Imaging 2004; 3: 333-342.